United States (USA) (US)

Fully automated epicardial adipose tissue volume and density measured from non-contrast CT predict major adverse cardiovascular events in asymptomatic subjects (2019) Mcelhinney P, Eisenberg E, Commandeur F, Chen X, Cadet S, Göller M, Cantu S, et al. Conference contribution Perivascular fat attenuation index stratifies the cardiac risk associated with high-risk plaque features on coronary computed tomography angiography (2019) Oikonomou EK, Mancio J, Kotanidis CK, Thomas KE, Alashi A, Centeno EH, Antonopoulos AS, et al. Conference contribution Automated quantification of epicardial adipose tissue from non-contrast CT on multi-center and multi-vendor data using deep learning (2019) Commandeur F, Göller M, Razipour A, Cadet S, Hell M, Kwiecinski J, Chen X, et al. Conference contribution Machine learning to predict the long-term risk of myocardial infarction and cardiac death based on clinical risk, coronary calcium and epicardial adipose tissue: a prospective study (2019) Commandeur FC, Slomka PJ, Göller M, Chen X, Cadet S, Razipour A, Gransar H, et al. Conference contribution Safeguarding 5G-and-Beyond Networks with Physical Layer Security (2019) Wu Y, Duong TQ, Swindlehurst AL Journal article, Editorial LUTATHERA (R) in first line therapy of G2 and G3 GEP-NETs (the NETTER-2 study) (2019) Ferone D, Pavel ME, Kunz P, De Herder W, Santoro P, Wegener A, Broberg P, et al. Conference contribution Facilitated Data Relay and Effects on Treatment of Severe Aortic Stenosis in Europe (2019) Steeds RP, Lutz M, Thambyrajah J, Serra A, Schulz E, Maly J, Aiello M, et al. Journal article Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations (2019) Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al. Conference contribution Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB) (2019) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) (2019) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, et al. Conference contribution